Anxiety and depression in patients with endometriosis: impact and management challenges

Antonio Simone Laganà1
Valentina Lucia La Rosa2
Agnese Maria Chiara Rapisarda3
Gaetano Valenti3
Fabrizio Sapia3
Benito Chiofalo1
Diego Rossetti4
Helena Ban Frangež5
Eda Vrtačnik Bokal5
Salvatore Giovanni Vitale1

1Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood “G Barresi”, University of Messina, Messina, 2Unit of Psychodiagnostics and Clinical Psychology, 3Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, 4Department of Maternal and Child Health, Gavardo Hospital, Brescia, Italy; 5Department of Reproduction, University Medical Center Ljubljana, Ljubljana, Slovenia

Abstract: Endometriosis is one of the most common gynecological diseases and affects ~10% of women in reproductive age. The most common clinical signs of endometriosis are menstrual irregularities, chronic pelvic pain (CPP), dysmenorrhea, dyspareunia and infertility. Symptoms of endometriosis often affect psychological and social functioning of patients. For this reason, endometriosis is considered as a disabling condition that may significantly compromise social relationships, sexuality and mental health. Considering this point, the aim of this narrative review is to elucidate the impact of anxiety and depression in the management of women with endometriosis. Psychological factors have an important role in determining the severity of symptoms, and women who suffer from endometriosis report high levels of anxiety, depression and other psychiatric disorders. In addition, endometriosis is one of the most important causes of CPP; women with endometriosis suffer from a wide range of pelvic pain such as dysmenorrhea, dyspareunia, nonmenstrual (chronic) pelvic pain, pain at ovulation, dyschezia and dysuria. Several studies have underlined the influence of CPP on quality of life and psychological well-being of women with endometriosis. Data suggest that the experience of pelvic pain is an important component of endometriosis and may significantly affect emotion functioning of affected women. It has been demonstrated that high levels of anxiety and depression can amplify the severity of pain. Further studies are needed to better understand the relationship between psychological factors and perception of pain. Treatment of endometriosis may be hormonal or surgical. Surgery is the primary treatment for more severe forms of endometriosis. There are few data in the literature about the influence of psychological factors and psychiatric comorbidities on the effectiveness of treatments. It is important to evaluate the presence of previous psychiatric diseases in order to select the most appropriate treatment for the patient.

Keywords: endometriosis, pelvic pain, anxiety, depression

Introduction

Endometriosis is one of the most common gynecological diseases and is defined as a benign and proliferative chronic disorder characterized by the ectopic presence and growth of functional endometrial tissue, glands and stroma, outside the uterine cavity.1–4 Endometriosis affects ~10% of women in reproductive age and up to 50% of infertile women.4–9 According to the classification of the American Society for Reproductive Medicine, there are four different stages of endometriosis; stages I and II represent initial stages, while stages III and IV are advanced stages.9 The stage of endometriosis is based on the location, amount, depth and size of the endometriotic foci. Specific criteria are the extent of the spread of the tissue, the involvement of pelvic structures, the extent of pelvic adhesions and the obstruction of the fallopian tubes.9,10 The stage of endometriosis does not necessarily correspond to the severity of symptoms, and hence a woman in stage I may experience very intense symptoms,
while a woman in stages II–III may have less intense symptoms and signs. The pathogenesis of the disease is not fully known, and several theories have been proposed to explain it. The most accepted theory suggests that immune dysfunction and abnormal differentiation of endometriotic tissue may be involved in the development of the disease. Other possible explanatory hypotheses include genetic, epigenetic or environmental factors. Moreover, the embryogenetic theory and the potential role of endocrine disruptors are other hypotheses considered to be plausible regarding the pathogenesis of endometriosis. The diagnosis of endometriosis is traditionally based on laparoscopic inspection of the pelvis and should ideally be confirmed by histological examination of the excised lesions. The most common clinical signs of endometriosis are menstrual irregularities, chronic pelvic pain (CPP), dysmenorrhea, dyspareunia and infertility. A significant proportion of women with endometriosis are asymptomatic, and the disease is often diagnosed during laparoscopic investigation due to other pelvic conditions. Three different clinical presentations of endometriosis have been described, peritoneal endometriosis, endometriotic ovarian cysts and deeply infiltrating endometriosis (DIE). DIE is the most aggressive presentation of endometriosis; it is characterized by an infiltration of >5 mm of endometrial tissue into the retroperitoneal space and accounts for ~20% of the cases. Symptoms of endometriosis can often affect psychological and social functioning of patients. For this reason, endometriosis is considered as a disabling condition that may significantly compromise social relationships, sexuality and mental health. Although the impact of endometriosis on mental health and psychological well-being has been investigated in several studies, data published so far are not robust enough to draw firm conclusion. Therefore, the aim of this narrative review is to elucidate the impact of anxiety and depression in the management of women with endometriosis.

Anxiety and depressive symptoms in women with endometriosis

As detailed below, several studies have reported the association between endometriosis and psychological diseases. Pope et al. underlined that endometriosis is related to a wide range of psychiatric symptoms, especially depression, anxiety, psychosocial stress and a poor quality of life. According to recent literature, depression and anxiety are the most common disorders associated with endometriosis. In this context, Low et al. investigated the possibility of a specific psychological profile associated with endometriosis. A total of 81 women with pelvic pain were studied, of whom 40 had endometriosis and 41 had other gynecological problems. Each patient completed six standardized psychometric tests (Eysenck Personality Questionnaire [EPQ], Beck Depression Inventory [BDI], General Health Questionnaire, State-Trait Anxiety Inventory [STAI], The Golombok Rust Inventory of Marital State and The Short-Form McGill Pain Questionnaire) to assess personality, psychopathology, marital state and pain. According to the results of their study, endometriosis patients showed higher psychoticism, introversion and anxiety scores than those of women with other gynecological conditions. In addition, a study by Laganà et al. investigated quality of life, negative emotions, such as anger, anxiety and depression, and possible psychopathological comorbidity in a sample of 166 women with endometriosis. Patients completed the following self-report instruments: Symptom Checklist-90-R, State-Trait Anger Expression Inventory-2, Self-Rating Anxiety Scale, Self-Rating Depression Scale and Quality of Life Index. The results showed that somatization, depression, sensitivity and phobic anxiety are higher in these patients than in women without endometriosis. Moreover, the same authors found that women with endometriosis are characterized by high levels of anxiety and a significant decline in quality of life. Chen et al. used the Taiwan National Health Insurance Research Database (NHIRD) with a longitudinal study design to identify women with endometriosis who were diagnosed with depression or anxiety disorders by board-certified psychiatrists. They found that endometriosis is associated with an elevated risk of developing depression and anxiety disorders.

In full agreement with these data, Sepulcri Rde and do Amaral evaluated depressive symptoms, anxiety and quality of life in 104 women with a diagnosis of pelvic endometriosis. The BDI and the Hamilton Rating Scale for Depression (HAM-D) were used to evaluate depressive symptoms; the Spielberger STAI and the Hamilton Rating Scale for Anxiety (HAM-A) to evaluate anxiety symptoms, and the short (26-item) version of the World Health Organization Quality of Life Assessment-BREF (WHOQOL-BREF) to evaluate quality of life. They found that 86.5% presented depressive symptoms and 87.5% presented anxiety and, most important, that psychiatric symptoms were not associated with endometriosis stage. In this study, age correlated positively with depressive symptoms, while there was no association between age and anxiety symptoms. Nevertheless, other authors found that only 29% of endometriotic women showed moderate to severe anxiety symptoms, while depression was present in 14.5%.
These apparently contradictory results may be due at least in part to different methodologies used to identify psychiatric symptoms or to selection biases (in particular, the inclusion of other comorbidities that can severely influence mental health). In addition, endometriotic patients show high levels of alexithymia, which further makes it difficult to identify other psychiatric disturbances, due to a severe difficulty in identifying and describing emotions. All the relevant information about the reported studies are summarized in Table 1.

Briefly, the literature confirms a significant incidence of anxiety, depression and psychopathological symptoms among women with endometriosis. These comorbidities could influence the severity of symptoms and the health-related quality of life of affected women.

The relation between endometriosis, pelvic pain and psychological diseases

The presence of CPP is an important variable to be taken into account when assessing the association between endometriosis and psychological diseases. CPP is defined as a nonmalignant pain perceived in pelvic areas that is constant or recurs over a period of 6 months. Endometriosis is one of the most common causes of CPP. Indeed, women with endometriosis may suffer from a wide range of pelvic pain such as dysmenorrhea, dyspareunia, nonmenstrual (chronic) pelvic pain, pain at ovulation, dyschezia and dysuria. It is important to underline that pain seems to be independent of the stage of endometriosis, so women with mild endometriosis may have intense pelvic pain while women with more severe endometriosis may suffer less from acute/chronic pain. This finding suggests that psychological factors may be involved, which influence pain experience in women with endometriosis. It has been demonstrated that pelvic pain has significant negative effects on women’s mental health and quality of life; in particular, women who suffer from pelvic pain report high levels of anxiety and depression, loss of working ability, limitations in social activities and a poor quality of life. Several studies have tried to investigate the relationship between endometriosis, pelvic pain and depression or anxiety disorders. Lorençatto et al compared the prevalence of depression between a group of women with a diagnosis of endometriosis and CPP and a group of women with endometriosis but no CPP. The presence and degree of depression were evaluated by using the BDI. The results of this study show that depression was present in 86% of the women with CPP and in 38% of the women without pain. Moreover, the symptoms associated with depression (somatic concerns, work inhibition, dissatisfaction and sadness) were significantly higher in women with pain. According to these data, depression may be the result of the experience of pelvic pain rather than of endometriosis itself. This hypothesis seems to be confirmed by the study performed by Souza et al, in which 57 patients aged between 25 and 48 years who underwent laparoscopy because of CPP were evaluated for quality of life and depressive symptoms. The WHOQOL-BREF was used to evaluate quality of life while the HAM-A and the BDI were used to investigate the presence of anxiety and depressive symptoms. According to their data analysis, CPP was correlated with lower quality of life and higher psychological disease. However, endometriosis in addition to CPP did not have an additional impact upon the quality of life. In this regard, Roth et al compared women suffering from CPP associated with endometriosis with women experiencing CPP due to other medical conditions. Participants completed a battery of validated questionnaires assessing demographic status, pain experience and other pain-related symptoms, pain disability, frequency of depressive symptoms, level of affective distress, satisfaction with pain treatment and satisfaction with their marital relationship. Interestingly, they did not find significant differences between the two groups for frequency of depressive symptoms and level of affective distress. Nevertheless, large cohort analyses found that women with endometriosis associated with pelvic pain reported higher levels of anxiety and depression and lower quality of life than women without pain symptoms, and healthy women. Although current data do not allow to draw firm conclusions, accumulating evidence suggests that psychopathological diseases might amplify pain symptoms in endometriotic patients and, in this way, contribute to create a vicious circle (psychopathological diseases → increased CPP → worsening of psychopathological diseases; Figure 1).

Summarizing the results of the abovementioned studies (Table 1), the experience of CPP should be considered as an important component of having endometriosis and may significantly affect women’s quality of life and psychological well-being. More specifically, psychiatric comorbidities associated with endometriosis seem to be an effect of the experience of pelvic pain rather than of endometriosis itself. The relationship between emotional diseases and perception of pain in women with endometriosis is still unclear. Studies on this topic have obtained controversial results; it has not yet been elucidated if depression, anxiety and emotional
### Table 1 Summary of the main studies investigating the association between psychological diseases and endometriosis

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of enrolled patients</th>
<th>Assessed symptoms/disorders</th>
<th>Questionnaires</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friedl et al&lt;sup&gt;21&lt;/sup&gt;</td>
<td>62 women with endometriosis, 61 healthy controls</td>
<td>Quality of life, anxiety and depression</td>
<td>Status of health questionnaire (SF-36), Hospital Anxiety and Depression Scale-German Version (HADS-D) and the Endometriosis Health Profile (EHP-30)</td>
<td>Moderate to severe anxiety symptoms were found in 29%; depressive symptoms were present in 14.5% of the patients. Both symptoms occurred in 12.9% Endometriosis patients showed higher psychosomatic, introversion and anxiety scores than women with other gynecological conditions</td>
</tr>
<tr>
<td>Low et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>81 women with chronic pelvic pain (CPP; 40 with endometriosis, 41 with other gynecological problems)</td>
<td>Personality, anxiety and depression</td>
<td>Eyenck Personality Questionnaire (EPQ), Beck Depression Inventory (BDI), General Health Questionnaire, State-Trait Anxiety Inventory (STAI), The Golombok Rust Inventory of Marital State and The Short-Form McGill Pain Questionnaire</td>
<td>Somatization, depression, sensitivity and phobic anxiety are higher in patients affected by endometriosis than in women without endometriosis Restoration of psychological medicine can improve women’s psychological health. Women with endometriosis reported significantly more pain symptoms, depression and anxiety symptoms compared with the control group</td>
</tr>
<tr>
<td>Laganà et al&lt;sup&gt;20&lt;/sup&gt;</td>
<td>166 women with endometriosis, 48 control patients with other benign monolateral adnexal diseases</td>
<td>Quality of life, negative emotions (anger, anxiety and depression) and possible psychopathological comorbidity</td>
<td>Symptom Checklist-90-R, State-Trait Anxiety Scale, Self-Rating Depression Scale and Quality of Life Index</td>
<td></td>
</tr>
<tr>
<td>De Graaf et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>83 women with endometriosis and their partners (n=74), 40 control women and their partners (n=26)</td>
<td>Dyspareunia, depressive symptoms and sexual functioning</td>
<td>The Dutch version of the Female Sexual Function Index (FSFI), the Short Form-12 (SF-12), the Pain Catastrophizing Scale (PCS), the Sexual Self-Consciousness Scale (SSCS), the Hospital Anxiety and Depression Scale (HADS) and an additional questionnaire</td>
<td></td>
</tr>
<tr>
<td>Chen et al&lt;sup&gt;28&lt;/sup&gt;</td>
<td>10,439 women with endometriosis (Taiwan National Health Insurance Research Database)</td>
<td>Association between endometriosis and anxiety or depressive symptoms</td>
<td>Diagnosis of depression or anxiety disorders given by board-certified psychiatrists</td>
<td>Endometriosis is associated with an elevated risk of developing depression and anxiety disorders</td>
</tr>
<tr>
<td>Cavaggioni et al&lt;sup&gt;21&lt;/sup&gt;</td>
<td>37 women with endometriosis and 43 healthy controls</td>
<td>Association between psychiatric disorders, psychopathological symptoms, alexithymia and endometriosis</td>
<td>Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV) Axis I Disorders Clinical Version (SCID-I cv), Symptom Checklist-90-Revised (SCL-90-R), Toronto Alexithymia Scale (TAS-20)</td>
<td>Psychoemotional distress and alexithymia are more frequent in women with endometriosis and might amplify pain symptoms in these patients</td>
</tr>
<tr>
<td>Sepulcri Rde and do Amaral&lt;sup&gt;23&lt;/sup&gt;</td>
<td>104 women with pelvic endometriosis</td>
<td>Depressive symptoms, anxiety and quality of life</td>
<td>BDI, Hamilton Rating Scale for Depression, Spielberger STAI, Hamilton Rating Scale for Anxiety and the short (26-item) version of the World Health Organization Quality Of Life instrument</td>
<td>86.5% of women presented depressive symptoms and 87.5% presented anxiety and, most important, psychiatric symptoms were not associated with endometriosis stage</td>
</tr>
<tr>
<td>Roth et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Women suffering from CPP secondary to endometriosis (n=30), women experiencing CPP due to either myofascial abdominal/pelvic pain (n=70) or pelvic adhesions (n=38)</td>
<td>Specific psychological variables associated with endometriosis</td>
<td>Chronic Pain Questionnaire (CPQ), BDI, Brief Symptom Inventory (BSI), McGill Pain Questionnaire (MPQ), Pain Disability Index (PDI)</td>
<td>No differences were obtained across the three groups for any of the measured outcomes</td>
</tr>
<tr>
<td>Waller and Shaw&lt;sup&gt;46&lt;/sup&gt;</td>
<td>49 women with minimal or mild endometriosis, 38 control women</td>
<td>Psychological differences between women with symptomatic as opposed to asymptomatic mild endometriosis</td>
<td>BDI, Spielberger STAI, Golombok Rust Inventory of Sexual Satisfaction (GRISS)</td>
<td>Women with pelvic pain symptoms, whether they had mild endometriosis or a normal pelvis, had similar scores for the BDI</td>
</tr>
<tr>
<td>Study</td>
<td>Subjects</td>
<td>Main Findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tripoli et al.⁹⁵</td>
<td>49 women with endometriosis, 35 patients with CPP diagnosed with another gynecological condition</td>
<td>Quality of life and sexual satisfaction of women who suffer from CPP with or without endometriosis. World Health Organization Quality of Life Assessment-BREF (WHOQOL-BREF) quality of life questionnaire and the GRISS. CPP caused by endometriosis or other gynecological conditions leads to a significant reduction of quality of life and sexual satisfaction. Higher pain scores are correlated with lower quality of life; however, the fact of having endometriosis in addition to CPP does not have an additional impact on the quality of life.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Souza et al.⁴⁴</td>
<td>57 women with CPP</td>
<td>Quality of life in women suffering from CPP due to endometriosis and other conditions. Visual analog scale (VAS), WHOQOL-BREF, The Hamilton Anxiety Rating Scale (HARS), BDI.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peveler et al.¹³</td>
<td>51 patients with medically unexplained pain and 40 patients with demonstrable endometriosis</td>
<td>Pain severity, mood symptoms, personality characteristics and social adjustment. BSI, BDI, General Health Questionnaire, EPQ, Social Adjustment Scale (SAS).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorençatto et al.⁴²</td>
<td>100 women with endometriosis (50 with CPP and 50 pain-free)</td>
<td>The prevalence of depression in women with endometriosis according to the presence or absence of pelvic pain. BDI. Depression is highly prevalent in women with endometriosis, especially those with pelvic pain. The study did not show any differences in levels of anxiety/depression between patients with pain and pain-free patients. Endometriosis patients with pelvic pain had poorer quality of life and mental health as compared with those with asymptomatic endometriosis and the healthy controls.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eriksen et al.³⁹</td>
<td>63 women with endometriosis (20 symptom free)</td>
<td>Psychological differences between women with and without pain symptoms. Coping Styles Questionnaire (CSQ), Courtauld Emotional Control Scale (CECS), BDI, STAI, Form Y-2.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facchin et al.⁴⁷</td>
<td>110 women with endometriosis (78 with pelvic pain and 32 without pain symptoms), 61 healthy controls</td>
<td>The impact of endometriosis on quality of life, anxiety and depression. SF-12, HADS.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
reason, psychiatric drugs may be considered as adjunctive with anxiety and depression during treatment.

GnRH agonists, which downregulate the pituitary and thereby indirectly the ovaries, have been commonly used as alternatives to gestagens and danazol in order to avoid a high rate of side effects such as weight gain, acne and headache. Although the GnRH agonists are effective in reducing endometriosis symptoms, they are often associated with anxiety and depression during treatment. For this reason, psychiatric drugs may be considered as adjunctive treatment during endometriosis therapy, even if they can produce side effects and some patients are reluctant to take additional drugs. There are few studies in the literature about the effects of hormonal treatment for endometriosis on quality of life and psychological functioning of affected women: Bergqvist and Theorell evaluated quality of life and psychiatric comorbidities in a sample of 48 women with endometriosis before, during, and after treatment with nafarelin or medroxyprogesterone acetate, using questionnaires that were both of a general and a more specific nature. They found that there was a significant reduction of symptoms during the study and important factors for quality of life such as sleep disturbances, anxiety and depression symptoms improved significantly after hormonal treatment. In partial agreement with the previous study, Zhao et al investigated the impact of progressive muscle relaxation (PMR) training on anxiety, depression and quality of life of patients with endometriosis undergoing GnRH agonist therapy. The patients were evaluated with STAI, Hospital Anxiety and Depression Scale – Depression subtest (HADS-D) and SF-36 before and after the PMR intervention. According to the results of this study, PMR training is effective in reducing anxiety and depressive symptoms, which could be associated with GnRH agonist therapy. However, it is important to evaluate previous psychiatric comorbidities that could increase the risk for psychiatric disturbance related to hormonal therapy for endometriosis.

Surgery is the primary treatment for more severe forms of endometriosis, such as DIE. Currently, several gynecological surgeons are attempting to modulate how much their surgery is radical according to fertility desires and future quality of life of the patient. To date, there are few data available in the literature on quality of life and anxiety and depression levels after surgery for endometriosis. A review by Degoara et al underlined that laparoscopic surgery is associated with improved quality of life and emotional well-being compared to medical therapies. A prospective cohort study by Van den Broeck et al evaluated depression levels, relationship satisfaction and sexual functioning of 203 women who underwent laparoscopic surgery for moderate or severe endometriosis. Participating patients completed the BDI, Dyadic Adjustment Scale (DAS) and the Short Sexual Functioning Scale (SSFS) 1 month prior to and 6, 12, 18 and 24 months after the intervention. Results showed that radical surgery for endometriosis improved the levels of depression and sexual functioning of the patients. These data suggest the importance of psychological factors not only for the severity of symptoms but also in the management of the disease and in the selection of the most appropriate therapy.

**Treatment of endometriosis and psychological effects**

Treatment of endometriosis can be complex and it is important to take into account several factors such as side effects, the anatomic type of endometriosis, role of previous surgery, infertility and future fertility desires. The main purpose of treatments should be pain control, improvement of the quality of life, prevention of disease recurrence, fertility preservation and reduction of anatomical damage. Hormonal treatment aims at downregulation of the ovaries, reducing the estrogen stimulation of endometriotic growth. The choice of the most appropriate hormonal therapy depends on several factors such as therapeutic effectiveness, tolerability, drug cost, physician’s experience and expected patient compliance. Combined oral contraceptives (COCs), danazol, gestrinone, medroxyprogesterone acetate and gonadotropin-releasing hormone (GnRH) agonists are the most frequently used drugs in the hormonal treatment of endometriosis. During the last few years, GnRH agonists, which downregulate the pituitary and thereby indirectly the ovaries, have been commonly used as alternatives to gestagens and danazol in order to avoid a high rate of side effects such as weight gain, acne and headache. Although the GnRH agonists are effective in reducing endometriosis symptoms, they are often associated with anxiety and depression during treatment. For this reason, psychiatric drugs may be considered as adjunctive treatment during endometriosis therapy, even if they can produce side effects and some patients are reluctant to take additional drugs. There are few studies in the literature about the effects of hormonal treatment for endometriosis on quality of life and psychological functioning of affected women: Bergqvist and Theorell evaluated quality of life and psychiatric comorbidities in a sample of 48 women with endometriosis before, during, and after treatment with nafarelin or medroxyprogesterone acetate, using questionnaires that were both of a general and a more specific nature. They found that there was a significant reduction of symptoms during the study and important factors for quality of life such as sleep disturbances, anxiety and depression symptoms improved significantly after hormonal treatment. In partial agreement with the previous study, Zhao et al investigated the impact of progressive muscle relaxation (PMR) training on anxiety, depression and quality of life of patients with endometriosis undergoing GnRH agonist therapy. The patients were evaluated with STAI, Hospital Anxiety and Depression Scale – Depression subtest (HADS-D) and SF-36 before and after the PMR intervention. According to the results of this study, PMR training is effective in reducing anxiety and depressive symptoms, which could be associated with GnRH agonist therapy. However, it is important to evaluate previous psychiatric comorbidities that could increase the risk for psychiatric disturbance related to hormonal therapy for endometriosis.

Surgery is the primary treatment for more severe forms of endometriosis, such as DIE. Currently, several gynecological surgeons are attempting to modulate how much their surgery is radical according to fertility desires and future quality of life of the patient. To date, there are few data available in the literature on quality of life and anxiety and depression levels after surgery for endometriosis. A review by Degoara et al underlined that laparoscopic surgery is associated with improved quality of life and emotional well-being compared to medical therapies. A prospective cohort study by Van den Broeck et al evaluated depression levels, relationship satisfaction and sexual functioning of 203 women who underwent laparoscopic surgery for moderate or severe endometriosis. Participating patients completed the BDI, Dyadic Adjustment Scale (DAS) and the Short Sexual Functioning Scale (SSFS) 1 month prior to and 6, 12, 18 and 24 months after the intervention. Results showed that radical surgery for endometriosis improved the levels of depression and sexual functioning of the patients. These data suggest the importance of psychological factors not only for the severity of symptoms but also in the management of the disease and in the selection of the most appropriate therapy.
Considering this scenario, we take the opportunity to solicit further studies to clarify the relationship between endometriosis therapies and psychological outcomes, taking into account other endometriosis-associated comorbidities such as infertility. In particular, it would be interesting to investigate whether a correlation occurs between psychological outcomes and levels of pro-inflammatory cytokines in peritoneal fluid, which are known to play a detrimental role in pain exacerbation and may contribute to endometriosis-related infertility.

**Conclusion**

Endometriosis is a very complex condition and psychological factors have an important role in determining the severity of symptoms and the effectiveness of the treatments. According to recent data, women with endometriosis are at risk for anxiety, depressive symptoms and other psychiatric disorders. Since it is still unclear if these comorbidities are a result of endometriosis itself or other factors such as CPP, we solicit further studies about this topic in order to better understand the relationship between endometriosis and psychological diseases. In addition, we take the opportunity to stress the importance of a multidisciplinary approach in the management of women with endometriosis. In this regard, psychological assessment is recommended in order to identify women at risk of developing symptoms of anxiety and depression and provide them an adequate psychological support. The aim should be to reduce as much as possible the impact of endometriosis on quality of life and psychological well-being of these patients.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


